Obermatt

Rohto Pharmaceutical

TYO:4527 · JP3982400008
Personal ProductsLarge

360

81
EV / EBIT59
Price / Owner Earnings67
Owner Earnings Yield79
Dividend Yield61
Price/Sales37
EV / Gross Profit58
Price/Book53
Return on Capital47
Cash Return on Capital64
Return on Equity46
EBIT Margin55
Gross Profitability41
Cash Conversion67
Accruals25
Owner Earnings Margin70
Sales growth49
Profit Growth29
Long-Term EPS Growth48
Reinvestment18
Price momentum85
Debt load57
Refinancing61
Debt Payback100
Liquidity69
Analyst ratings56
Opinion Changes50
Price Target Upside63
Market mood85
Value Creation13/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Rohto Pharmaceutical clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryJapan
IndustryPersonal Products
SizeLarge
TypePublic Company
ExchangeTSE
Founded1949
Employees153
ISINJP3982400008
Last UpdateApr 2, 2026
Index & Theme
OphthalmologyDermatologyLifestyleNutraceuticalHealth DiagnosticsConsumer GoodsHealth CareManufacturing

Description

Analysis

Middle-of-the-road

Rohto Pharmaceutical Co.,Ltd. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is attractive. You pay 12.2× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone. At today's price, the market is assuming roughly -0% yearly growth; analysts expect 5%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is adequate. The company scores 13/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
87
2023202420252026

All-time high

87

Jun 2026

All-time low

36

Jan 2024

Average rank

63

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
37
52
42
56
Price/Earnings
57
62
51
49
Price/Book
53
34
37
59
Dividend Yield
61
52
39
31
Value (overall)
47
59
40
51

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Rohto Pharmaceutical with its peers
WuXi AppTec
SHH:603259
99
CountryChina
IndustryLife Sciences Tools & Services
SizeX-Large
Full Stock Analysis →
Daewon Pharmaceutical
KSC:003220
46
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Cosmax
KSC:192820
30
CountrySouth Korea
IndustryPersonal Products
SizeMedium
Full Stock Analysis →
Kao
TYO:4452
60
CountryJapan
IndustryPersonal Products
SizeX-Large
Full Stock Analysis →
Alfresa Holdings
TYO:2784
70
CountryJapan
IndustryHealth Care Providers & Services
SizeX-Large
Full Stock Analysis →
Kolmar Korea
KSC:161890
53
CountrySouth Korea
IndustryPersonal Products
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →